Similar Papers

Paper Title
Journal
Date
Author
EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer – preliminary data on safety and tolerability.
Sebastian Yves Friedrich Michels ... Martin Hellmich
Journal of Clinical Oncology | VOL. 37
Sebastian Yves Friedrich Michels, et. al.Sebastian Yves Friedrich Michels ... Martin Hellmich
20 May 2019

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma
Sandra P D'Angelo ... Neeta Somaiah
Journal of Clinical Oncology | VOL. -
Sandra P D'Angelo, et. al.Sandra P D'Angelo ... Neeta Somaiah
21 Jan 2025
De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?
Jordi Remon ... Benjamin Besse
Journal of Clinical Oncology | VOL. -
Jordi Remon, et. al.Jordi Remon ... Benjamin Besse
21 Jan 2025
Reply to: Automatic for the People: What Has Machine Learning Analysis of Positron Emission Tomography Left for the Physician?
Skander Jemaa ... Richard A.D Carano
Journal of Clinical Oncology | VOL. -
Skander Jemaa, et. al.Skander Jemaa ... Richard A.D Carano
21 Jan 2025
Automatic for the People: What Has Machine Learning Analysis of Positron Emission Tomography Left for the Physician?
Vít Procházka ... Jaroslav Ptáček
Journal of Clinical Oncology | VOL. -
Vít Procházka, et. al.Vít Procházka ... Jaroslav Ptáček
21 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.